|
|
|
|
|
|
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期- |
|
作用机制Receptor interacting protein kinase (RIPK) family inhibitors |
|
|
|
|
最高研发阶段临床申请批准 |
首次获批国家/地区- |
首次获批日期- |
A Randomised, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR9900 after Oral Administrations in Healthy Elderly Volunteers
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Preliminary Efficacy of SIR1-365 in Adult Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome
A Randomized, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR9900 after Oral Administrations in Healthy Adult Volunteers
100 项与 Sironax Aus Pty Ltd 相关的临床结果
0 项与 Sironax Aus Pty Ltd 相关的专利(医药)
100 项与 Sironax Aus Pty Ltd 相关的药物交易
100 项与 Sironax Aus Pty Ltd 相关的转化医学